- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Senju Pharma. Co., LTO v. Lupin Ltd.
Finding that defendants infringe claims 6, 12-16 and that claims 6, 12-16 of the patent-in-suit are invalid for obviousness.
Fall 2013

Case Name: Senju Pharma. Co., LTO v. Lupin Ltd., Civ. No. 11-271-SLR (Consol.), 2013 U.S. Dist. LEXIS 112439 (D. Del. August 9, 2013) (Robinson, J.)
Drug Product and Patent(s)-in-Suit: Zymar® and Zymaxid® (gatifloxacin/disodium edetate); U.S. Pat. No. 6,333,045 (“the ’045 patent”)
Nature of the Case and Issue(s) Presented: The Court previously found that claims 1-3, 6, 7, and 9 of the ’045 patent were infringed, but invalid. The ’045 patent was the subject of a reexamination proceeding and claims 6, 12-16 emerged. Defendants raised collateral estoppel arguments, but the court declined to entertain them. The court previously determined that the plaintiffs did not fully litigate a claim with a limitation of 0.01 w/v% disodium edetate (“EDTA”). The court found that defendants infringed claims 12-16 of the ’045 patent because they presented no evidence of non-infringement at trial and their experts testified that they were not asked to opine on infringement of the reexamined claims. The court also found that defendants infringed claim 6. Claim 6 is a method claim using the components of claim 12. The court construed claim 6 as requiring “an increased concentration of gatifloxacin in the aqueous humor.” Plaintiffs did not test defendants’ ANDA products. Rather, plaintiffs demonstrated that the inclusion of EDTA in the formulation created increased concentration of gatifloxacin, and expert testimony supported that conclusion. The court also rejected defendants’ additional non-infringement arguments. Finally, the court found the patents obvious in view of the prior art. Defendants presented a prima facie case of obviousness, which was not rebutted by plaintiffs’ claim of unexpected results.
Why Defendants Prevailed: Relying on previous findings concerning the nature of the prior art, the court found the differences between the prior art and the re-examined claims minimal. Those differences were: (i) using 0.3 w/v% to 0.8 w/v% gatifloxacin; (ii) having a pH of above 5 to 6; and (iii) using 0.01 w/v% EDTA to increase corneal permeability. The court adopted its previous analysis concerning the use of gatifloxacin and EDTA. The prior art explicitly recites the claimed concentration range of gatifloxacin and the use of 0.01 w/v% of EDTA. The court also found that the pH range did not distinguish the claims from the prior art since pH ranges from 3 to 6.5 were disclosed in the prior art.
With respect to claim 6, the method claim, plaintiffs argued that the prior art did not demonstrate that its formulation would increase corneal permeability. The court disagreed. Relying on its previous findings, the court found that the prior art demonstrated that one of ordinary skill in the art would understand that EDTA concentrations lower than 0.5 w/v% would be effective when calcium was added. Thus, the asserted claims were prima facie obvious. In response, plaintiffs contended that the claimed invention achieved unexpected results. In particular, plaintiffs argued that the increase in corneal permeability was greater than expected. The court rejected that argument since the increased magnitude was a product of routine optimization that would have been obvious to one skilled in the art.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.